Shoulder Innovations reports Q3 EPS (64c), consensus (37c)

Reports Q3 revenue $11.8M, consensus $9.87M. As of September 30 cash and cash equivalents, and marketable securities totaled $137M, which includes an aggregate of approximately $115M of gross proceeds from the issuance of the company’s convertible notes in July and initial public offering, which closed on August 1. “We are very excited about our accelerating momentum through 2025, with first-half year-over-year revenue growth of 37% expanding to 58% in the Q3 enabling us to increase our full-year revenue guidance,” said Rob Ball, CEO of Shoulder Innovations (SI). “We continue to add new surgeon customers and drive rapid adoption of our advanced implant systems, while maintaining our focus on delivering additional innovations to market.”